COMPARE · Data as of August 21, 2026
ALNY vs HALO
Verdict: Side-by-side breakdown using the Bull Rankings model. ALNY scored 75.0, HALO scored 79.5 — HALO leads.
Compare another set
ALNY
Alnylam Pharmaceuticals, Inc.
75
$236.22 · $31.6B
fundamentals as of
Score gap
4.5
HALO leads
HALO
Halozyme Therapeutics, Inc.
79.5
$108.17 · $12.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestHALO31.7x
- Fastest growthALNY+65.2%
- Highest qualityHALO96 / 100
- Largest discount to fair valueHALO-38%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ALNY
stronger →← stronger
HALO
67
Qualityreturns · margins · balance sheet
96
99
Growthrevenue & earnings expansion
97
64
Valuevaluation vs sector peers
54
ALNY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ALNY
HALO
$465mC
FCF
$806mC+
+65.2%A
Rev
+41.2%A
2.21D
D/E
—
41.2xC
P/E
31.7xB
0.46A
PEG
1.47B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ALNY
HALO
189% above
Price vs fair valuelower is cheaper
38% below
~43%/yr
Growth the price implies10-yr FCF · lower = less priced in
~1%/yr
-74%
1-yr DCF upside
+29%
-65%
5-yr DCF upside
+63%
-48%
10-yr DCF upside
+129%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ALNY
Why this score
- Diluting shareholders
HALO
Why this score
- Buying back stock
- Durable high returns
The companies
ALNYAlnylam Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $31.6b. Down 52% from 52-week high of $495.55 — deep drawdown territory. Revenue growing +65% — in hypergrowth territory. PEG 0.46 — paying under fair value for the growth rate. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $370.20 (implying +57% upside).
Moat
Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 54% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.21 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $12.3b. Trading near 52-week high of $108.49 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $99.56 (implying -8% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 32x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ALNY and HALO diverge
On the headline score the gap is 4.5 points in favor of HALO. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityALNY 66.8 · HALO 95.7HALO +28.9
- ValueALNY 64.1 · HALO 54.1ALNY +10.0
- GrowthALNY 98.5 · HALO 97.0level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.